GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (OTCPK:DMKPQ) » Definitions » Cyclically Adjusted PB Ratio

DMK Pharmaceuticals (DMK Pharmaceuticals) Cyclically Adjusted PB Ratio : 0.00 (As of Jun. 08, 2024)


View and export this data going back to 1995. Start your Free Trial

What is DMK Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-06-08), DMK Pharmaceuticals's current share price is $0.03. DMK Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was $58.18. DMK Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for DMK Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, DMK Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 71.11. The lowest was 0.01. And the median was 1.90.

DMKPQ's Cyclically Adjusted PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.875
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

DMK Pharmaceuticals's adjusted book value per share data for the three months ended in Sep. 2023 was $-0.524. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $58.18 for the trailing ten years ended in Sep. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


DMK Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for DMK Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMK Pharmaceuticals Cyclically Adjusted PB Ratio Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.64 2.17 0.98 1.01 0.23

DMK Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.23 0.15 0.04 0.01

Competitive Comparison of DMK Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DMK Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where DMK Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



DMK Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

DMK Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.03/58.18
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DMK Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, DMK Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book=Book Value per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.524/129.8595*129.8595
=-0.524

Current CPI (Sep. 2023) = 129.8595.

DMK Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201312 71.314 98.326 94.185
201403 81.243 99.695 105.825
201406 64.365 100.560 83.119
201409 84.808 100.428 109.662
201412 0.000 99.070 0.000
201503 92.506 99.621 120.585
201506 77.408 100.684 99.839
201509 64.348 100.392 83.236
201512 48.541 99.792 63.166
201603 45.223 100.470 58.451
201606 60.771 101.688 77.607
201609 82.973 101.861 105.780
201612 80.469 101.863 102.586
201703 64.574 102.862 81.522
201706 85.525 103.349 107.463
201709 96.511 104.136 120.351
201712 82.909 104.011 103.513
201803 70.121 105.290 86.484
201806 53.247 106.317 65.038
201809 85.595 106.507 104.363
201812 69.113 105.998 84.671
201903 58.693 107.251 71.066
201906 49.680 108.070 59.697
201909 45.769 108.329 54.865
201912 37.362 108.420 44.750
202003 31.535 108.902 37.604
202006 21.895 108.767 26.141
202009 20.475 109.815 24.212
202012 2.609 109.897 3.083
202103 25.950 111.754 30.154
202106 21.947 114.631 24.863
202109 16.207 115.734 18.185
202112 12.111 117.630 13.370
202203 7.433 121.301 7.957
202206 3.287 125.017 3.414
202209 1.328 125.227 1.377
202212 -0.377 125.222 -0.391
202303 -4.071 127.348 -4.151
202306 -4.238 128.729 -4.275
202309 -0.524 129.860 -0.524

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


DMK Pharmaceuticals  (OTCPK:DMKPQ) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


DMK Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Executives
Dorbin John W. Jr. officer: General Counsel C/O ARCIMOTO, INC., 2034 WEST 2ND AVENUE, EUGENE OR 97402
Seth Cohen officer: CFO C/O NEWTEK BUSINESS SERVICES,INC, 1440 BROADWAY, NEW YORK NY 10018
Ebrahim Versi director, officer: CEO 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Jannine Versi director 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Vickie S Reed director TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David J. Marguglio director 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Carlo Dennis J Phd director, 10 percent owner, officer: President/CEO PO BOX 1176, RANCHO SANTA FE CA 92067
Ronald B. Moss officer: Chief Medical Officer 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
David C. Benedicto officer: Chief Financial Officer 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Meera J. Desai director 1682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Robert O Hopkins officer: Chief Financial Officer 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Karen K. Daniels officer: Vice President of Operations 11455 EL CAMINO REAL, SUITE 310, SAN DIEGO CA 92130
Howard C Birndorf director C/O NANOGEN INC, 10398 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Roshawn A. Blunt director 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Richard C Williams director 26001 OSPREY NEST COURT, BONITA SPRINGS FL 34134